These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 32366911)

  • 1. The Impact of Liposomal Irinotecan on the Treatment of Advanced Pancreatic Adenocarcinoma: Real-World Experience in a Taiwanese Cohort.
    Su YY; Chiang NJ; Tsai HJ; Yen CJ; Shan YS; Chen LT
    Sci Rep; 2020 May; 10(1):7420. PubMed ID: 32366911
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nanoliposomal irinotecan plus fluorouracil and folinic acid as a second-line treatment option in patients with metastatic pancreatic ductal adenocarcinoma: a retrospective cohort study.
    Park SJ; Kim H; Shin K; Hong TH; Suh JH; Lee MA
    BMC Cancer; 2021 Nov; 21(1):1176. PubMed ID: 34732161
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Liposomal irinotecan in metastatic pancreatic adenocarcinoma in Asian patients: Subgroup analysis of the NAPOLI-1 study.
    Bang YJ; Li CP; Lee KH; Chiu CF; Park JO; Shan YS; Kim JS; Chen JS; Shim HJ; Rau KM; Choi HJ; Oh DY; Belanger B; Chen LT
    Cancer Sci; 2020 Feb; 111(2):513-527. PubMed ID: 31789476
    [TBL] [Abstract][Full Text] [Related]  

  • 4. NAPOLI-1 phase 3 study of liposomal irinotecan in metastatic pancreatic cancer: Final overall survival analysis and characteristics of long-term survivors.
    Wang-Gillam A; Hubner RA; Siveke JT; Von Hoff DD; Belanger B; de Jong FA; Mirakhur B; Chen LT
    Eur J Cancer; 2019 Feb; 108():78-87. PubMed ID: 30654298
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nanoliposomal irinotecan with fluorouracil for the treatment of advanced pancreatic cancer, a single institution experience.
    Glassman DC; Palmaira RL; Covington CM; Desai AM; Ku GY; Li J; Harding JJ; Varghese AM; O'Reilly EM; Yu KH
    BMC Cancer; 2018 Jun; 18(1):693. PubMed ID: 29945562
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nanoliposomal irinotecan with 5-fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy: A real-world experience.
    Yu HY; Lee CY; Lin LG; Chao Y; Li CP
    J Chin Med Assoc; 2022 Jan; 85(1):42-50. PubMed ID: 34759212
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quality of life in metastatic pancreatic cancer patients receiving liposomal irinotecan plus 5-fluorouracil and leucovorin.
    Hubner RA; Cubillo A; Blanc JF; Melisi D; Von Hoff DD; Wang-Gillam A; Chen LT; Becker C; Mamlouk K; Belanger B; Yang Y; de Jong FA; Siveke JT
    Eur J Cancer; 2019 Jan; 106():24-33. PubMed ID: 30458340
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Survival with nal-IRI (liposomal irinotecan) plus 5-fluorouracil and leucovorin versus 5-fluorouracil and leucovorin in per-protocol and non-per-protocol populations of NAPOLI-1: Expanded analysis of a global phase 3 trial.
    Chen LT; Siveke JT; Wang-Gillam A; Li CP; Bodoky G; Dean AP; Shan YS; Jameson GS; Macarulla T; Lee KH; Cunningham D; Blanc JF; Chiu CF; Schwartsmann G; Braiteh FS; Mamlouk K; Belanger B; de Jong FA; Hubner RA
    Eur J Cancer; 2018 Dec; 105():71-78. PubMed ID: 30414528
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Liposomal irinotecan and 5-fluorouracil/leucovorin in older patients with metastatic pancreatic cancer - A subgroup analysis of the pivotal NAPOLI-1 trial.
    Macarulla T; Blanc JF; Wang-Gillam A; Chen LT; Siveke JT; Mirakhur B; Chen J; de Jong FA
    J Geriatr Oncol; 2019 May; 10(3):427-435. PubMed ID: 30842038
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Liposomal irinotecan plus fluorouracil/leucovorin in older patients with advanced pancreatic cancer: a single-center retrospective study.
    Nagashima S; Kobayashi S; Tsunoda S; Yamachika Y; Tozuka Y; Fukushima T; Morimoto M; Ueno M; Furuse J; Maeda S
    Int J Clin Oncol; 2024 Feb; 29(2):188-194. PubMed ID: 37991558
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical outcomes of liposomal irinotecan in patients with advanced pancreatic cancer previously treated with conventional irinotecan: A meta-analysis of real-world evidence.
    Gupta A; De Jesus-Acosta A; Le D; Pishvaian M; Zaidi N; Zheng L; Laheru D
    Cancer; 2024 Nov; 130(21):3734-3744. PubMed ID: 38985839
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of previous S-1 treatment on efficacy of liposomal irinotecan plus 5-fluorouracil and leucovorin in patients with metastatic pancreatic cancer.
    Tang CY; Yang SH; Li CP; Su YY; Chiu SC; Bai LY; Shan YS; Chen LT; Chuang SC; Chan DC; Yen CJ; Peng CM; Chiu TJ; Chen YY; Chen JS; Chiang NJ; Chou WC
    Pancreatology; 2024 Jun; 24(4):600-607. PubMed ID: 38565467
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of nanoliposomal irinotecan plus fluorouracil/leucovorin in the continuum of care of patients with metastatic pancreatic ductal adenocarcinoma.
    Procaccio L; Merz V; Fasano M; Vaccaro V; Giommoni E; Pretta A; Noventa S; Satolli MA; Giordano G; Zichi C; Pinto C; Zecchetto C; Barsotti G; De Vita F; Milella M; Antonuzzo L; Scartozzi M; Zaniboni A; Spadi R; Casalino S; Bergamo F; De Toni C; Melisi D; Lonardi S
    Cancer Med; 2023 Jul; 12(13):14337-14345. PubMed ID: 37278395
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Liposomal Irinotecan: A Review in Metastatic Pancreatic Adenocarcinoma.
    Frampton JE
    Drugs; 2020 Jul; 80(10):1007-1018. PubMed ID: 32557396
    [TBL] [Abstract][Full Text] [Related]  

  • 15. nal-IRI+5-FU/LV versus 5-FU/LV in post-gemcitabine metastatic pancreatic cancer: Randomized phase 2 trial in Japanese patients.
    Ueno M; Nakamori S; Sugimori K; Kanai M; Ikeda M; Ozaka M; Furukawa M; Okusaka T; Kawabe K; Furuse J; Komatsu Y; Ishii H; Sato A; Shimizu S; Chugh P; Tang R; Ioka T
    Cancer Med; 2020 Dec; 9(24):9396-9408. PubMed ID: 33099898
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early dose reduction/delay and the efficacy of liposomal irinotecan with fluorouracil and leucovorin in metastatic pancreatic ductal adenocarcinoma (mPDAC): A post hoc analysis of NAPOLI-1.
    Chen LT; Macarulla T; Blanc JF; Mirakhur B; de Jong FA; Belanger B; Bekaii-Saab T; Siveke JT
    Pancreatology; 2021 Jan; 21(1):192-199. PubMed ID: 33214082
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Irinotecan hydrochloride liposome HR070803 in combination with 5-fluorouracil and leucovorin in locally advanced or metastatic pancreatic ductal adenocarcinoma following prior gemcitabine-based therapy (PAN-HEROIC-1): a phase 3 trial.
    Cui J; Qin S; Zhou Y; Zhang S; Sun X; Zhang M; Cui J; Fang W; Gu K; Li Z; Wang J; Chen X; Yao J; Zhou J; Wang G; Bai Y; Xiao J; Qiu W; Wang B; Xia T; Wang C; Kong L; Yin J; Zhang T; Shen X; Fu D; Gao C; Wang H; Wang Q; Wang L
    Signal Transduct Target Ther; 2024 Sep; 9(1):248. PubMed ID: 39300077
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of nanoliposomal irinotecan (nal-IRI, MM-398, PEP02) in the management of metastatic pancreatic cancer.
    Chiang NJ; Chang JY; Shan YS; Chen LT
    Expert Opin Pharmacother; 2016 Jul; 17(10):1413-20. PubMed ID: 27140876
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical outcomes of liposomal irinotecan in advanced pancreatic adenocarcinoma patients previously treated with conventional irinotecan-based chemotherapy: a real-world study.
    Gupta A; De Jesus-Acosta A; Zheng L; Lee V; Kamel I; Le D; Pishvaian M; Laheru D
    Front Oncol; 2023; 13():1250136. PubMed ID: 37700832
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Liposomal Irinotecan + 5-FU/LV in Metastatic Pancreatic Cancer: Subgroup Analyses of Patient, Tumor, and Previous Treatment Characteristics in the Pivotal NAPOLI-1 Trial.
    Macarulla Mercadé T; Chen LT; Li CP; Siveke JT; Cunningham D; Bodoky G; Blanc JF; Lee KH; Dean A; Belanger B; Wang-Gillam A
    Pancreas; 2020 Jan; 49(1):62-75. PubMed ID: 31856081
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.